USD 2.08
(-2.35%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -373 Thousand USD | -9.06% |
2022 | -342 Thousand USD | -626.15% |
2021 | 65 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -97 Thousand USD | -134.64% |
2024 Q2 | -100 Thousand USD | -3.09% |
2023 Q2 | -100 Thousand USD | -16.28% |
2023 Q4 | 280 Thousand USD | 0.0% |
2023 FY | -373 Thousand USD | -9.06% |
2023 Q3 | - USD | 100.0% |
2023 Q1 | -86 Thousand USD | 11.34% |
2022 FY | -342 Thousand USD | -626.15% |
2022 Q4 | -97 Thousand USD | 0.0% |
2021 FY | 65 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ADC Therapeutics SA | 67.02 Million USD | 100.556% |
Annovis Bio, Inc. | - USD | Infinity% |
Biohaven Pharmaceutical Holding Company Ltd. | -3.36 Million USD | 88.928% |
Ginkgo Bioworks Holdings, Inc. | 197.45 Million USD | 100.189% |
Nuvation Bio Inc. | -222 Thousand USD | -68.018% |
Nuvation Bio Inc. | -222 Thousand USD | -68.018% |
Arcus Biosciences, Inc. | -223 Million USD | 99.833% |
Zymeworks Inc. | -66.97 Million USD | 99.443% |